gene	source	drug	drugType	cancerType	level	hmfLevel	evidenceType	significance	hmfResponse
RET	oncoKb	Vandetanib	Pan-TK inhibitor	Non-Small Cell Lung Cancer	3A	C	Predictive	Responsive	Responsive
RET	oncoKb	Cabozantinib	Pan-kinase inhibitor	Non-Small Cell Lung Cancer	2A	B	Predictive	Responsive	Responsive
ALK	cgi	Alectinib	ALK inhibitor	Non-small cell lung	FDA guidelines	A	Predictive	Responsive	Responsive
ALK	cgi	Ceritinib	ALK inhibitor	Non-small cell lung	FDA guidelines	A	Predictive	Responsive	Responsive
ALK	civic	Pemetrexed	Unknown	Non-small Cell Lung Carcinoma	B	B	Predictive	Sensitivity	Responsive
ALK	civic	Crizotinib	ALK inhibitor;MET inhibitor	Non-small Cell Lung Carcinoma	A	A	Predictive	Sensitivity	Responsive
ALK	civic	Crizotinib	ALK inhibitor;MET inhibitor	Non-small Cell Lung Carcinoma	B	B	Predictive	Sensitivity	Responsive
